Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.

@article{Nabhan2016DiseaseTA,
  title={Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.},
  author={Chadi Nabhan and Xiaolei Zhou and Bann-mo Day and Keith C Dawson and Andrew D. Zelenetz and Jonathan W. Friedberg and James R. Cerhan and Brian K Link and Christopher R Flowers},
  journal={American journal of hematology},
  year={2016},
  volume={91 8},
  pages={
          770-5
        }
}
We aimed to comprehensively study sex differences in disease and patients' characteristics, treatment and outcomes in patients with follicular lymphoma (FL) in the United States (USA) utilizing the National LymphoCare Study registry (2004-2014). Among evaluable males (n = 1277) and females (n = 1375) with FL, females less commonly received anthracyclines and were more likely to receive rituximab monotherapy. Overall response rates were comparable between sex groups. With a median follow-up of 8… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 8 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Randomized trial of bendamustine-rituximab or RCHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study

IW Flinn, R van der Jagt, BS Kahl
2014
View 7 Excerpts
Highly Influenced

Follicular Lymphoma International Prognostic Index.

Current treatment options in oncology • 2006
View 5 Excerpts
Highly Influenced

Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: Results from the SEXIE-R-CHOP-14 trial of the DSHNHL

M Pfreundschuh, GH SZ
J Clin Oncol • 2014
View 3 Excerpts